This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

New England Journal Of Medicine Releases Study Showing GSK's FluLaval Quadrivalent Vaccine Effective In Preventing Seasonal Flu In Children

GSK has developed two quadrivalent vaccines that the U.S. Food and Drug Administration have licensed for use.  GSK markets these vaccines as FluLaval ® Quadrivalent and Fluarix ® Quadrivalent. Both vaccines are approved to be administered to individuals three years and older, and they have been shown to have comparable safety and tolerability to three-strain (trivalent) seasonal influenza vaccines.  Complete prescribing information for both vaccines is available at us.gsk.com.

About Seasonal Influenza

Seasonal influenza may cause three to five million cases of severe illness and up to 500,000 deaths per year worldwide.  Vaccination against influenza is considered one of the most effective ways of preventing mortality, complications and hospitalizations.  The U.S. Centers for Disease Control and Prevention (CDC) recommends that children six months of age and older and adults receive an influenza shot annually.  More information about seasonal influenza can be found at http://flu.gov and http://www.cdc.gov/flu/about/season/flu-season-2012-2013.htm.

Indication for FluLaval Quadrivalent

FluLaval Quadrivalent is a vaccine indicated for active immunization for the prevention of disease caused by influenza A subtype viruses and type B viruses contained in the vaccine.  FluLaval Quadrivalent is approved for use in persons 3 years of age and older.

Indication for Fluarix Quadrivalent

Fluarix Quadrivalent is a vaccine indicated for active immunization for the prevention of disease caused by influenza A subtype viruses and type B viruses contained in the vaccine.  Fluarix Quadrivalent is approved for use in persons 3 years of age and older.

Important Safety Information for FluLaval Quadrivalent and Fluarix Quadrivalent

  • Do not administer FluLaval Quadrivalent or Fluarix Quadrivalent to anyone with known severe allergic reactions (anaphylaxis) to any component of the vaccine, including egg protein, or a life‐threatening reaction to previous administration of any influenza vaccine.
  • If Guillain-Barre syndrome has occurred within 6 weeks of receipt of a prior influenza vaccine, the decision to give FluLaval Quadrivalent or Fluarix Quadrivalent should be based on careful consideration of the potential benefits and risks.
  • The tip caps of the Fluarix Quadrivalent prefilled syringes may contain natural rubber latex which may cause allergic reactions in latex-sensitive individuals.
  • Syncope (fainting) can occur in association with administration of injectable vaccines. Procedures should be in place to avoid falling injury and to restore cerebral perfusion following syncope
  • If FluLaval Quadrivalent or Fluarix Quadrivalent is administered to immunosuppressed persons, including individuals receiving immunosuppressive therapy, the immune response may be lower than in immunocompetent persons.
  • In clinical trials with FluLaval Quadrivalent, the most common solicited local adverse reaction in adults was pain.  The most common solicited systemic adverse reactions in adults were muscle aches, headache, fatigue and arthralgia.  In children 3 through 17 years of age, the most common solicited local adverse reaction was pain.  In children 3 through 4 years of age, the most common solicited systemic adverse reactions were irritability, drowsiness, and loss of appetite.  In children 5 through 17 years of age, the most common solicited systemic adverse reactions were muscle aches, fatigue, headache, arthralgia, and gastrointestinal symptoms.  (See Adverse Reactions section of the Prescribing Information for FluLaval Quadrivalent for other potential adverse reactions and events).
  • In clinical trials with Fluarix Quadrivalent, the most common injection site adverse reaction in adults was pain.  The most common systemic adverse reactions in adults were muscle aches, headache, and fatigue.  In children 3 through 17 years of age, injection site adverse reactions were pain, redness, and swelling. In children 3 through 5 years of age, the most common systemic adverse reactions were drowsiness, irritability, and loss of appetite.  In children 6 through 17 years of age, the most common systemic adverse reactions were fatigue, muscle aches, headache, arthralgia, and gastrointestinal symptoms.  (See Adverse Reactions section of the Prescribing Information for Fluarix Quadrivalent for other potential adverse reactions and events).
  • Vaccination with FluLaval Quadrivalent or Fluarix Quadrivalent may not result in protection in all vaccine recipients.

GSK – one of the world's leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer.  For further information go to  us.gsk.com, follow us on  twitter.com/GSKUS or visit our  blog( www.morethanmedicine.us.gsk.com/blog/). 

Cautionary statement regarding forward-looking statementsGSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect GSK' s operations are described under Item 3.D 'Risk factors' in the company's Annual Report on Form 20-F for 2012.

[1] Moderately severe influenza was defined as fever greater than 39°C or physician-confirmed acute otitis media or lower respiratory illness (shortness of breath, pulmonary congestion, pneumonia, bronchiolitis, bronchitis, wheezing, croup) or serious extra-pulmonary complication including myositis, encephalitis, seizure, or myocarditis.

SOURCE GlaxoSmithKline plc

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
2 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,083.80 -2.83 -0.02%
S&P 500 1,987.98 +0.97 0.05%
NASDAQ 4,472.1080 -1.5890 -0.04%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs